CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $244,546 | -5.4% | 4,356 | -23.8% | 0.23% | -4.1% |
| Q1 2023 | $258,625 | +11.3% | 5,718 | 0.0% | 0.24% | +22.7% |
| Q4 2022 | $232,437 | -37.9% | 5,718 | 0.0% | 0.20% | -43.8% |
| Q3 2022 | $374,000 | +4.2% | 5,718 | 0.0% | 0.35% | +27.5% |
| Q1 2022 | $359,000 | -29.2% | 5,718 | -14.5% | 0.28% | -23.3% |
| Q4 2021 | $507,000 | -43.7% | 6,687 | -16.8% | 0.36% | -49.2% |
| Q3 2021 | $900,000 | -30.0% | 8,037 | +1.2% | 0.71% | -28.6% |
| Q2 2021 | $1,286,000 | +33.5% | 7,943 | +0.5% | 0.99% | +25.4% |
| Q1 2021 | $963,000 | -26.0% | 7,901 | -7.1% | 0.79% | +79.1% |
| Q4 2020 | $1,302,000 | +32.5% | 8,505 | -27.6% | 0.44% | +7.6% |
| Q3 2020 | $983,000 | +41.8% | 11,748 | +24.6% | 0.41% | +15.5% |
| Q2 2020 | $693,000 | – | 9,428 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |